Frank J Simutis
Overview
Explore the profile of Frank J Simutis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
54
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chorley B, Atabakhsh E, Doran G, Gautier J, Ellinger-Ziegelbauer H, Jackson D, et al.
Crit Rev Toxicol
. 2021 May;
51(3):264-282.
PMID: 34038674
MicroRNAs (miRNAs) are small non-coding RNA that regulate the expression of messenger RNA and are implicated in almost all cellular processes. Importantly, miRNAs can be released extracellularly and are stable...
2.
Urinary miRNA Biomarkers of Drug-Induced Kidney Injury and Their Site Specificity Within the Nephron
Chorley B, Ellinger-Ziegelbauer H, Tackett M, Simutis F, Harrill A, McDuffie J, et al.
Toxicol Sci
. 2020 Dec;
180(1):1-16.
PMID: 33367795
Drug-induced kidney injury (DIKI) is a major concern in both drug development and clinical practice. There is an unmet need for biomarkers of glomerular damage and more distal renal injury...
3.
Simutis F, Sanderson T, Pilcher G, Graziano M
Toxicol Sci
. 2019 Jun;
171(1):98-116.
PMID: 31165171
Avagacestat, a gamma (γ)-secretase inhibitor that was in development for treatment of Alzheimer's disease, produced ovarian granulosa-thecal cell tumors in rats and dogs and a glomerulopathy with profound proteinuria in...
4.
Simutis F, Sanderson T, Pilcher G, Graziano M
Toxicol Sci
. 2018 Mar;
163(2):525-542.
PMID: 29529279
The toxicity of avagacestat, a sulfonamide-based gamma (γ)-secretase inhibitor that was in development as a treatment for Alzheimer's disease, was evaluated in a comprehensive nonclinical toxicology program that included 6-month...
5.
Discovery and Preclinical Evaluation of BMS-955829, a Potent Positive Allosteric Modulator of mGluR5
Yang F, Snyder L, Balakrishnan A, Brown J, Sivarao D, Easton A, et al.
ACS Med Chem Lett
. 2016 Mar;
7(3):289-93.
PMID: 26985317
Positive allosteric modulators (PAMs) of the metabotropic glutamate receptor subtype 5 (mGluR5) are of interest due to their potential therapeutic utility in schizophrenia and other cognitive disorders. Herein we describe...
6.
Simutis F, Jones D, Hostetter J
Vet Immunol Immunopathol
. 2007 Feb;
116(1-2):1-12.
PMID: 17275098
The function of gammadelta T cells during ruminant paratuberculosis (Johne's disease) is presently unknown. An ex vivo system was used to test the hypothesis that gammadelta T cells are capable...
7.
Pressel M, Fox L, Apley M, Simutis F
J Feline Med Surg
. 2005 Sep;
7(5):317-21.
PMID: 16182186
A 12-year-old, neutered male domestic shorthair cat was evaluated with a life-long history of intermittent, predominantly small bowel diarrhea and a 3 day history of hematochezia. At presentation, the cat...
8.
Simutis F, Cheville N, Jones D
Am J Vet Res
. 2005 Apr;
66(3):474-82.
PMID: 15822593
Objective: To characterize the early cellular immune response to Mycobacterium avium subsp paratuberculosis (MAP) infection and evaluate the development of granulomatous inflammation at the SC injection site in experimentally inoculated...